Corticosteroids in the Treatment of Tuberculous Pleurisy
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00338793
Recruitment Status :
First Posted : June 20, 2006
Last Update Posted : August 26, 2008
Guangxi Medical University
National Natural Science Foundation of China
Ministry of Education, China
Bureau of Science and Technology of Guangxi Province, China
Tuberculous pleurisy is associated with inflammation and fibrosis. Adjunctive corticosteroids are used for tuberculous pleurisy because their anti-inflammatory effect is thought to minimise pleural reactivity and thereby reduce residual pleural thickening. The purpose is to evaluate the efficacy and safety of oral prednisolone for treatment of adult patients with tuberculous pleurisy.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Signed written informed consent;
Presented with clinical features suggesting pleural tuberculosis;
Had not previously received treatment or prophylaxis for tuberculosis;
Had not recently received treatment with glucocorticoids;
Were not pregnant or breast-feeding.
Failed to complete the screening procedures;
Were seropositive for HIV
Had risk factors for serious steroid-related adverse events (a history of diabetes or positive urine glucose, a history or clinical finding of hypertension, or a history of peptic ulcer disease or mental illness);
Standard doses of antituberculosis drugs could not be used (as in participants with concurrent liver disease)